LÓPEZ-GRUESO , María José

Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma (HCC) in de-differentiation stage (presenting epithelial–mesenchymal transition, EMT). We studied the role of the thioredoxin system (Trx1/TrxR1) in the sensitivity or resistance of HCC cells to the treatment with Sorafenib. As a model, we used a set of...

Cancer cells have unlimited replicative potential, insensitivity to growth-inhibitory signals, evasion of apoptosis,cellular stress, and sustained angiogenesis, invasiveness and metastatic potential. Cancer cells adequately adaptcell metabolism and integrate several intracellular and redox signaling to promote cell survival in an in-flammatory...